Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Revenue of Amylyx Pharmaceuticals, Inc. (AMLX)
Revenue in 2023 (TTM): $380.79 M
According to Amylyx Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $380.79 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Amylyx Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $380.79 M | $355.35 M | $39.89 M | $54.3 M | $49.27 M |
| 2022 | $22.23 M | $19.24 M | $-201,341,000 | $-197,601,000 | $-198,375,000 |
| 2021 | $285 K | $233 K | $-82,688,000 | $-87,931,000 | $-87,879,000 |
| 2020 | $650 K | $-23,944,000 | $-38,721,000 | $-42,280,000 | $-44,837,000 |
| 2019 | $1.43 M | $-10,473,000 | $-13,379,000 | $-13,716,000 | $-14,816,000 |